Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Bertoldo

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Current Cancer Drug Targets|January 22, 2010
Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical settingDaniele Santini, Vladimir Virzi, Maria Elisabetta Fratto, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2010
Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusionFrancesco Bertoldo, Serena Pancheri, Sonia Zenari, et al.
BMC Cancer|March 7, 2006
The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?Maria Teresa Valenti, Francesco Bertoldo, Luca Dalle Carbonare, et al.
Journal of Bone Oncology|January 14, 2025
Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMSFrancesco Bertoldo, Cristina Eller-Vainicher, Vittorio Fusco, et al.
Calcified Tissue International|January 4, 2020
Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot StudyAngelo Fassio, Giovanni Adami, Alessandro Giollo, et al.
Archives of Osteoporosis|June 18, 2026
Under-recognized, under-referred: a multidisciplinary evaluation of fragility fracture management in the emergency settingFrancesco Bertoldo, Fabio De Iaco, Carlo Trevisan, et al.
Research Quarterly for Exercise and Sport|August 4, 2023
Bone Mineral Density in Mountain, Road Cyclists and Untrained Controls: Exercise, Diet and HormonesFrancesco Zamboni, Pietro Ferrari, Lucia Cazzoletti, et al.
Nutrients|May 14, 2022
The Potential Impact of Inducing a Restriction in Reimbursement Criteria on Vitamin D Supplementation in Osteoporotic Patients with or without FracturesLuca Degli Esposti, Valentina Perrone, Stefania Sella, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 16, 2022
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienistsRodolfo Mauceri, Rita Coniglio, Antonia Abbinante, et al.
Endocrine|September 20, 2025
Safety of Romosozumab in women with cancer and osteoporosis at high risk of fracturesRoberto Colle, Alberto Piasentier, Alessandro Fanti, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Current Cancer Drug Targets|January 22, 2010
Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical settingDaniele Santini, Vladimir Virzi, Maria Elisabetta Fratto, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2010
Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusionFrancesco Bertoldo, Serena Pancheri, Sonia Zenari, et al.
BMC Cancer|March 7, 2006
The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?Maria Teresa Valenti, Francesco Bertoldo, Luca Dalle Carbonare, et al.
Journal of Bone Oncology|January 14, 2025
Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMSFrancesco Bertoldo, Cristina Eller-Vainicher, Vittorio Fusco, et al.
Calcified Tissue International|January 4, 2020
Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot StudyAngelo Fassio, Giovanni Adami, Alessandro Giollo, et al.
Archives of Osteoporosis|June 18, 2026
Under-recognized, under-referred: a multidisciplinary evaluation of fragility fracture management in the emergency settingFrancesco Bertoldo, Fabio De Iaco, Carlo Trevisan, et al.
Research Quarterly for Exercise and Sport|August 4, 2023
Bone Mineral Density in Mountain, Road Cyclists and Untrained Controls: Exercise, Diet and HormonesFrancesco Zamboni, Pietro Ferrari, Lucia Cazzoletti, et al.
Nutrients|May 14, 2022
The Potential Impact of Inducing a Restriction in Reimbursement Criteria on Vitamin D Supplementation in Osteoporotic Patients with or without FracturesLuca Degli Esposti, Valentina Perrone, Stefania Sella, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 16, 2022
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienistsRodolfo Mauceri, Rita Coniglio, Antonia Abbinante, et al.
Endocrine|September 20, 2025
Safety of Romosozumab in women with cancer and osteoporosis at high risk of fracturesRoberto Colle, Alberto Piasentier, Alessandro Fanti, et al.
Pageof 8